神经平素对抗剂 (NRPas) 阻断癌症治疗关键因子p38α酶触发细胞死亡的酸化
Lucia Borriello1,2,3, Rafika Jarray3,4, Rachel Rignault-Bricard5,6
1Department of Cancer and Cellular Biology, Lewis Katz School of Medicine, Temple University, Philadelphia, PA 19140, USA.
Molecules (Basel, Switzerland)
|April 26, 2025
概括
两种新型神经平素抗剂 (NRPas) 抑制VEGF-A/NRP-1结合,影响癌细胞信号传递. 这些NRPas通过降低关键蛋白质的调节来诱导细胞死亡,并特别准p38α-酶酸化.
科学领域:
- 在瘤学瘤学.
- 分子生物学分子生物学
- 生物化学 生物化学
背景情况:
- 神经皮林-1 (NRP-1) 是癌症治疗中的关键标,但其精确的作用机制需要进一步阐明.
- 小抑制分子是研究NRP-1的作用和开发向癌症治疗的重要工具.
研究的目的:
- 研究新型神经平素抗体 (NRPa-47和NRPa-48) 对三阴性乳腺癌细胞中信号通路的影响.
- 确定这些NRPas的特异性和下游影响,特别是关于MAPK和p38α-酶酸化.
主要方法:
- 用NRPa-47和NRPa-48治疗MDA-MB-231三阴性乳腺癌细胞.
- 对VEGF受体酸化和下游信号级联的分析,包括各种MAPK通路.
- 在体外激酶测试中,评估NRPas的特异性与40个激酶的小组相比.
主要成果:
- NRPa-47和NRPa-48抑制了VEGF-A/NRP-1结合,降低了VEGF受体酸化,并调节了下游级联.
- NRPas对JNK,ERK和p38β/γ/δ酸化有不同的影响,但通常下调p38α-酶酸化.
- 实验室试验证实,NRPas专门向p38α-激酶而不会影响其他测试的激酶,通过调节与亡相关的蛋白质,热冲击蛋白质,细胞循环调节剂和转录因子诱导细胞死亡.
结论:
- NRPa-47和NRPa-48代表了研究NRP-1在癌症中的功能强大的小分子.
- 这些NRPas通过降低关键信号通路的调节,特别是p38α-酶酸化,诱导癌细胞死亡.
- 这些发现支持将NRPas与p38α-激酶抑制剂结合起来,以加强癌症治疗的潜在治疗策略.
相关概念视频
01:22Amplifying Signals via Enzymatic Cascade
8.2K
When a ligand binds to a cell-surface receptor, the receptor's intracellular domain changes shape, which may either activate its enzyme function or allow its binding to other molecules. The initial signal is amplified by most signal transduction pathways. This means that a single ligand molecule can activate multiple molecules of a downstream target. Proteins that relay a signal are most commonly phosphorylated at one or more sites, activating or inactivating the protein. Kinases catalyze...
8.2K
01:19Interactions Between Signaling Pathways
6.1K
Signaling cascades usually lack linearity. Multiple pathways interact and regulate one another, allowing cells to integrate and respond to diverse environmental stimuli.
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...
6.1K
01:31The Intrinsic Apoptotic Pathway
5.6K
Internal cellular stress, such as cellular injury or hypoxia, triggers intrinsic apoptosis. The B-cell lymphoma 2 (Bcl-2) family of proteins are the primary regulators of the intrinsic apoptotic pathway. For example, during DNA damage, checkpoint proteins, such as Ataxia Telangiectasia Mutated (ATM protein) and Checkpoints Factor-2 (Chk2) proteins, are activated. These proteins phosphorylate p53 which further activates pro-apoptotic proteins, such as Bax, Bak, PUMA, and Noxa, and inhibits...
5.6K
01:20The JAK-STAT Signaling Pathway
8.4K
Several cytokine receptors have tightly bound Janus kinase or JAK proteins attached at their cytosolic tail. Small signaling molecules such as cytokines, growth hormones, or prolactins bind to the cytokine receptors and initiate their dimerization. The dimerization brings the cytosolic JAKs together that trans-phosphorylate and activates each other. The activated JAKs now phosphorylate cytosolic tails of the cytokine receptors, which serve as binding sites for adaptor proteins such as SH2...
8.4K
01:17The Extrinsic Apoptotic Pathway
5.5K
The extrinsic apoptotic pathway is initiated when extracellular death-inducing signals, such as specific cytokines, activate the death receptors expressed on the cell surface. The immune cells involved in this pathway are natural killer cells (NK cells) and cytotoxic T-lymphocytes. NK cells are critical in innate immune response, while cytotoxic T-lymphocytes are associated with adaptive immune response. These cells recognize specific receptors expressed on the altered cells and activate...
5.5K
01:22PI3K/mTOR/AKT Signaling Pathway
3.3K
The mammalian target of rapamycin (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1 (mTORC1) and mTOR complex 2 (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast, mTORC2 consists of a...
3.3K